Can Fluoroquinolones Increase the Risk of Aortic Aneurysm?

Quick Answer

Research into fluoroquinolone aortic aneurysm risk has found a possible association between antibiotics such as ciprofloxacin, levofloxacin, and moxifloxacin and an increased risk of aortic aneurysm or aortic dissection. These findings have prompted regulatory agencies such as the FDA and the European Medicines Agency to issue safety communications advising caution for patients with existing vascular risk factors. In 2018, the FDA issued a specific safety communication warning that fluoroquinolones may increase the occurrence of aortic aneurysm and dissection.

Because of these findings, fluoroquinolone-associated vascular risks have become an important topic in recent antibiotic safety discussions.

Introduction

Fluoroquinolones are a class of broad-spectrum antibiotics used to treat a wide range of bacterial infections. Common medications in this group include ciprofloxacin, levofloxacin, and moxifloxacin.

In recent years, researchers have examined whether fluoroquinolones may affect connective tissues throughout the body. These concerns were first recognized through reports of tendon injuries, but additional studies have investigated possible links to vascular complications. The topic of fluoroquinolone aortic aneurysm risk has received growing attention in medical literature.

These discussions often arise in the broader context of fluoroquinolone toxicity, a term used to describe a cluster of rare but potentially significant adverse effects reported with this class of antibiotics.

What Is an Aortic Aneurysm?

An aortic aneurysm occurs when a section of the aorta (the largest artery in the body) becomes weakened and begins to bulge outward.

The aorta carries oxygen-rich blood from the heart to the rest of the body. If the vessel wall becomes weakened, the affected section may enlarge over time.

In some cases, an aneurysm can progress to an aortic dissection, a condition in which the inner layer of the artery tears. Both conditions are considered serious and require medical evaluation.

Research Linking Fluoroquinolones to Aortic Aneurysm

Several large observational studies have explored a potential relationship between fluoroquinolone use and aortic complications.

Some studies have reported a higher incidence of aortic aneurysm or dissection in the weeks following fluoroquinolone treatment compared with other antibiotics. These findings have been observed in certain patient populations, particularly older adults and individuals with underlying cardiovascular conditions. Several population-based studies have reported an increased relative risk of aortic aneurysm in patients exposed to fluoroquinolones compared with matched controls.

Because these studies are observational, they show associations rather than direct causation. Researchers continue to investigate whether factors such as infection severity, underlying health conditions, or medication interactions may contribute to the observed risks.

Possible Biological Mechanisms

Researchers have proposed several mechanisms that might explain why fluoroquinolones could affect connective tissue.

One hypothesis involves the way fluoroquinolones may influence collagen metabolism. Collagen is a key structural protein found in tendons, ligaments, and the walls of blood vessels. The aortic wall relies on both collagen and elastin for its structural integrity, and disruption of either protein may compromise vessel wall strength.

Laboratory studies have suggested that fluoroquinolones may increase oxidative stress and alter cellular processes involved in maintaining connective tissue integrity. Some researchers have also explored possible effects on matrix metalloproteinases, enzymes involved in collagen remodeling.

These mechanisms remain an active area of scientific research.

Who May Be at Higher Risk?

Regulatory agencies have suggested that certain groups may have a higher baseline risk for aortic complications.

These may include individuals with existing aortic aneurysm or vascular disease, hypertension, genetic connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, and advanced age.

For this reason, medical guidance in some regions recommends that healthcare providers carefully weigh the risks and benefits of fluoroquinolones in patients with known vascular risk factors.

When Could Symptoms Occur?

In studies examining aortic complications, the potential increased risk appeared to occur during treatment or within the weeks following fluoroquinolone exposure.

However, these events remain rare. Most patients who take fluoroquinolone antibiotics do not experience vascular complications.

Any symptoms such as sudden severe chest pain, abdominal pain, or back pain should always be evaluated by a healthcare professional.

Current Medical Understanding

The current scientific understanding is that fluoroquinolone antibiotics may be associated with a small increased risk of aortic aneurysm or dissection in certain populations.

Because the evidence comes primarily from observational research, scientists continue to study the mechanisms and clinical significance of this association.

Medical decisions regarding antibiotics should always involve a discussion between patients and healthcare providers about the benefits and risks of treatment.

Frequently Asked Questions